CA3207440A1 - Amiselimod for preventing, treating, or ameliorating ulcerative colitis - Google Patents

Amiselimod for preventing, treating, or ameliorating ulcerative colitis Download PDF

Info

Publication number
CA3207440A1
CA3207440A1 CA3207440A CA3207440A CA3207440A1 CA 3207440 A1 CA3207440 A1 CA 3207440A1 CA 3207440 A CA3207440 A CA 3207440A CA 3207440 A CA3207440 A CA 3207440A CA 3207440 A1 CA3207440 A1 CA 3207440A1
Authority
CA
Canada
Prior art keywords
dose
subject
amiselimod
administration
administration period
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3207440A
Other languages
English (en)
French (fr)
Inventor
Jimin Lee
Neal SLATKIN
Ezra R. LOWE
Zeev HEIMANSON
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bausch Health Ireland Ltd
Original Assignee
Bausch Health Ireland Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bausch Health Ireland Ltd filed Critical Bausch Health Ireland Ltd
Publication of CA3207440A1 publication Critical patent/CA3207440A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Luminescent Compositions (AREA)
  • Cereal-Derived Products (AREA)
CA3207440A 2021-02-08 2022-02-08 Amiselimod for preventing, treating, or ameliorating ulcerative colitis Pending CA3207440A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163147060P 2021-02-08 2021-02-08
US63/147,060 2021-02-08
PCT/EP2022/053030 WO2022167690A1 (en) 2021-02-08 2022-02-08 Amiselimod for preventing, treating, or ameliorating ulcerative colitis

Publications (1)

Publication Number Publication Date
CA3207440A1 true CA3207440A1 (en) 2022-08-11

Family

ID=80447376

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3207440A Pending CA3207440A1 (en) 2021-02-08 2022-02-08 Amiselimod for preventing, treating, or ameliorating ulcerative colitis

Country Status (9)

Country Link
US (1) US20240299318A1 (cg-RX-API-DMAC7.html)
EP (1) EP4288041A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024506041A (cg-RX-API-DMAC7.html)
CN (1) CN116940350A (cg-RX-API-DMAC7.html)
AU (1) AU2022217475A1 (cg-RX-API-DMAC7.html)
CA (1) CA3207440A1 (cg-RX-API-DMAC7.html)
MX (1) MX2023009249A (cg-RX-API-DMAC7.html)
TW (1) TW202245742A (cg-RX-API-DMAC7.html)
WO (1) WO2022167690A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025134072A1 (en) * 2023-12-21 2025-06-26 Bausch Health Ireland Limited Methods for preventing, treating, or ameliorating ulcerative colitis in certain patient populations with amiselimod

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4256108A (en) 1977-04-07 1981-03-17 Alza Corporation Microporous-semipermeable laminated osmotic system
US4160452A (en) 1977-04-07 1979-07-10 Alza Corporation Osmotic system having laminated wall comprising semipermeable lamina and microporous lamina
US4265874A (en) 1980-04-25 1981-05-05 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
RU2433117C2 (ru) 2005-12-15 2011-11-10 Мицубиси Танабе Фарма Корпорейшн Аминное соединение и его применение в медицинских целях
MX367667B (es) 2008-12-22 2019-08-30 Novartis Ag Régimen de dosificación de un agonista de los receptores de s1p.
MA40775A (fr) * 2014-10-01 2017-08-08 Respivert Ltd Dérivé d'acide 4-(4-(4-phényluréido-naphtalén -1-yl) oxy-pyridin-2-yl) amino-benzoïque utilisé en tant qu'inhibiteur de la kinase p38
CA3002540C (en) * 2015-01-06 2023-11-07 Arena Pharmaceuticals, Inc. Use of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid for treating conditions related to the s1p1 receptor
US20180228778A1 (en) * 2015-08-11 2018-08-16 Akaal Pharma Pty Ltd Compositions comprising s1p receptor modulators
WO2018237379A2 (en) * 2017-06-23 2018-12-27 Enzo Biochem, Inc. Sphingosine pathway modulating compounds for the treatment of cancers
TWI721483B (zh) * 2018-07-13 2021-03-11 美商基利科學股份有限公司 吡咯并[1,2-b]嗒𠯤衍生物
CN113613640B (zh) * 2018-09-08 2024-11-29 谭文 肾上腺素能β2受体激动剂R-对映体在治疗炎症性肠病及其肠外疾病的新应用
US20220390464A1 (en) * 2019-07-30 2022-12-08 Children's Medical Center Corporation Methods and compositions for characterizing inflammatory bowel disease

Also Published As

Publication number Publication date
JP2024506041A (ja) 2024-02-08
TW202245742A (zh) 2022-12-01
EP4288041A1 (en) 2023-12-13
AU2022217475A1 (en) 2023-08-24
CN116940350A (zh) 2023-10-24
WO2022167690A1 (en) 2022-08-11
MX2023009249A (es) 2023-10-23
US20240299318A1 (en) 2024-09-12

Similar Documents

Publication Publication Date Title
JP6244497B1 (ja) 選択的s1p1レセプターアゴニストの投与法
JP4938905B2 (ja) 選択的s1p1レセプターアゴニストの投与法
AU2013205648B2 (en) Combination treatment
KR101801864B1 (ko) 인플루엔자, 감기 및 염증의 치료에서 레보세티리진 및 몬테루카스트의 용도
CA2829947A1 (en) Dosing regimens for the treatment of fabry disease
WO2010042548A2 (en) Methods of treating inflammation
KR102495432B1 (ko) 중등증 내지 중증의 호산성 천식을 치료하기 위한 레슬리주맙의 용도
TW200800206A (en) Methods for determining how to treat congestive heart failure
JP7713489B2 (ja) B因子阻害剤の使用方法
JP2024531314A (ja) 小児msを治療するためのオファツムマブ
US20240299318A1 (en) Amiselimod for preventing, treating or ameliorating ulcerative colitis
JP6890340B6 (ja) グルカゴン受容体アンタゴニスト抗体を用いた心不全の治療法
JP2025106329A (ja) ベンラリズマブを使用した強化された患者個体群における慢性閉塞性肺疾患を治療するための方法
WO2025134072A1 (en) Methods for preventing, treating, or ameliorating ulcerative colitis in certain patient populations with amiselimod
JP2018135278A (ja) 循環器疾患及び/又はミトコンドリア病の改善用医薬
EA051860B1 (ru) Способ профилактики, лечения или облегчения язвенного колита
HK40094222A (en) Amiselimod for preventing, treating, or ameliorating ulcerative colitis
JP2021510157A (ja) 内皮細胞機能障害を調節するためのrps2ペプチドの使用
WO2021203013A2 (en) Methods of treating immune mediated pulmonary injury
KR20220074913A (ko) S1p1 수용체와 관련된 상태를 치료하는 방법
WO2025209479A1 (en) Methods of treatment of immune thrombocytopenia using sovleplenib
EP4616867A1 (en) Combination of endothelin receptor antagonist and glucocorticoid for treating iga nephropathy
Home Highlights in Ulcerative Colitis From the 18th Congress of ECCO
US20230330089A1 (en) Covid prevention and treatment using an integrin inhibitor
TW202539688A (zh) 使用索樂匹尼布處置溫型自體免疫性溶血性貧血的方法

Legal Events

Date Code Title Description
MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250124

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20250124

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250124

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED

Effective date: 20260109

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT

Effective date: 20260109

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20260109

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD

Year of fee payment: 4

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260122

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260122

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20260219

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT

Effective date: 20260219

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20260219

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20260219

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260219

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20260219